Literature DB >> 18300796

Muscularis mucosae duplication and the musculo-fibrous anomaly in endoscopic mucosal resections for barrett esophagus: implications for staging of adenocarcinoma.

Jason T Lewis1, Kenneth K Wang, Susan C Abraham.   

Abstract

Endoscopic mucosal resection (EMR) is increasingly used for management of Barrett esophagus (BE)-related neoplasia. Duplication of the muscularis mucosae (MM) has been described in BE esophagectomy specimens, where it can pose difficulties with accurate staging of carcinoma. The frequency, morphologic characteristics, and effect of MM duplication in adenocarcinoma staging in EMRs have not yet been evaluated. We studied 122 EMR specimens from 100 patients from 1999 to 2006. The following histologic features were scored: depth of EMR, presence of MM duplication and its extent, prolapse changes (extension of smooth muscle into lamina propria), gland entrapment, and diagnosis (original and study/final). Carcinomas reaching the level of submucosa were classified as invasive adenocarcinoma (INV); those confined to lamina propria or MM were classified as intramucosal adenocarcinoma (IMAC). Of 122 EMRs, 11 (9%) reached mucosa only, 109 (89%) extended to submucosa, and 2 (2%) extended into muscularis propria. MM duplication was present in 67% (75 of 111 specimens that reached at least submucosa). Prolapse changes were noted in 65 (54%) cases and gland entrapment in 67 (56%). Final pathologic diagnoses were 9 (7%) no specialized Barrett mucosa, 4 (3%) BE without dysplasia, 13 (11%) low-grade dysplasia, 51 (42%) high-grade dysplasia, 33 (27%) IMAC, and 12 (10%) INV. EMRs without BE were less likely to show MM duplication (P = 0.01) and there was a trend toward less frequent prolapse change (P = 0.08) and less gland entrapment (P = 0.08) as compared with EMRs with BE. However, there were no significant differences with respect to MM duplication, prolapse change, or gland entrapment between BE with or without dysplasia, IMAC, or INV. Among 33 cases of IMAC, tumor invaded lamina propria in 10 (30%), inner or single MM in 14 (42%), space between duplicated MM in 5 (15%), and outer MM layer in 4(12%). Lymphatic invasion was seen in 2 (10%) cases in which tumor reached the space between MM layers. Overstaging of carcinomas occurred in the original reports in 8 (7%) cases due to misinterpretation of the muscular anatomy, including one case in which the deep MM was interpreted as muscularis propria. These results show that MM duplication is commonly seen in EMR specimens. It is closely associated with the presence of BE but is not affected by neoplastic progression in the Barrett epithelium. Pathologists need to be aware of this distinctive anatomy of BE for accurate staging of adenocarcinomas, particularly to avoid mistaking a thickened outer MM as muscularis propria. Level of IMAC may be a critical feature because of potential access to lymphatic spaces between duplicated MM layers, and we therefore recommend including an explicit statement about the depth of adenocarcinoma invasion rather than using only broad terms such as IMAC or INV in the diagnostic report.

Entities:  

Mesh:

Year:  2008        PMID: 18300796     DOI: 10.1097/PAS.0b013e31815bf8c7

Source DB:  PubMed          Journal:  Am J Surg Pathol        ISSN: 0147-5185            Impact factor:   6.394


  18 in total

Review 1.  Barrett's Esophagus: A Comprehensive and Contemporary Review for Pathologists.

Authors:  Bita V Naini; Rhonda F Souza; Robert D Odze
Journal:  Am J Surg Pathol       Date:  2016-05       Impact factor: 6.394

2.  Clinical and histologic determinants of mortality for patients with Barrett's esophagus-related T1 esophageal adenocarcinoma.

Authors:  Cadman L Leggett; Jason T Lewis; Tsung Teh Wu; Cathy D Schleck; Alan R Zinsmeister; Kelly T Dunagan; Lori S Lutzke; Kenneth K Wang; Prasad G Iyer
Journal:  Clin Gastroenterol Hepatol       Date:  2014-08-20       Impact factor: 11.382

Review 3.  Barrett esophagus: histology and pathology for the clinician.

Authors:  Robert D Odze
Journal:  Nat Rev Gastroenterol Hepatol       Date:  2009-07-07       Impact factor: 46.802

4.  8th edition AJCC/UICC staging of cancers of the esophagus and esophagogastric junction: application to clinical practice.

Authors:  Thomas W Rice; Deepa T Patil; Eugene H Blackstone
Journal:  Ann Cardiothorac Surg       Date:  2017-03

Review 5.  Endoscopic mucosal resection in the management of esophageal neoplasia: current status and future directions.

Authors:  Vikneswaran Namasivayam; Kenneth K Wang; Ganapathy A Prasad
Journal:  Clin Gastroenterol Hepatol       Date:  2010-06-10       Impact factor: 11.382

Review 6.  History, molecular mechanisms, and endoscopic treatment of Barrett's esophagus.

Authors:  Stuart Jon Spechler; Rebecca C Fitzgerald; Ganapathy A Prasad; Kenneth K Wang
Journal:  Gastroenterology       Date:  2010-01-18       Impact factor: 22.682

Review 7.  Endoscopic and surgical resection of T1a/T1b esophageal neoplasms: a systematic review.

Authors:  George Sgourakis; Ines Gockel; Hauke Lang
Journal:  World J Gastroenterol       Date:  2013-03-07       Impact factor: 5.742

8.  Depth of submucosal invasion does not predict lymph node metastasis and survival of patients with esophageal carcinoma.

Authors:  Rami J Badreddine; Ganapathy A Prasad; Jason T Lewis; Lori S Lutzke; Lynn S Borkenhagen; Kelly T Dunagan; Kenneth K Wang
Journal:  Clin Gastroenterol Hepatol       Date:  2009-11-27       Impact factor: 11.382

Review 9.  Mucosal ablation of Barrett esophagus.

Authors:  Irving Waxman; Vani J A Konda
Journal:  Nat Rev Gastroenterol Hepatol       Date:  2009-06-02       Impact factor: 46.802

10.  Endoscopic mucosal resection results in change of histologic diagnosis in Barrett's esophagus patients with visible and flat neoplasia: a multicenter cohort study.

Authors:  Sachin Wani; Julian Abrams; Steven A Edmundowicz; Srinivas Gaddam; Christine E Hovis; Daniel Green; Neil Gupta; April Higbee; Ajay Bansal; Amit Rastogi; Dayna Early; Charles J Lightdale; Prateek Sharma
Journal:  Dig Dis Sci       Date:  2013-04-30       Impact factor: 3.199

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.